David Beier, J.D.

Mr. Beier has served as a member of our board since December 2017. Mr. Beier brings extensive experience in the biopharmaceutical industry, particularly in areas such as healthcare policy, government affairs, regulatory affairs, pricing, healthcare economics and product commercialization. He is currently a Managing Director at Bay City Capital, where he has been since 2013. He also serves as an appointee of Governor Brown on the California State Government Organization and the Economy Commission. In addition, Mr. Beier is an advisor to the Parker Institute for Cancer Immunotherapy. Previously, Mr. Beier served in the White House as Chief Domestic Policy Advisor to Vice President Gore during the Clinton Administration. He served as an appointee of President Clinton on his Advisory Committee for Trade Policy and Negotiations, on the Institute of Medicine panel on the Future of Health and Human Services, and as an advisor to the President’s Council of Advisors on Science and Technology. Mr. Beier was formerly a partner at Hogan and Hartson and Counsel to the U.S. House of Representatives Committee on the Judiciary. Mr. Beier’s industry experience includes 9 years at Genentech as Vice President, Government Affairs and Policy as well as over 10 years at Amgen as Senior Vice President, Global Government Affairs and Corporate Affairs, where he had responsibility for public policy, coverage and reimbursement, payor planning, healthcare economics, communications and philanthropy. He received his J.D. from Albany Law School at Union University and his undergraduate degree and Colgate University. He is admitted to practice law in New York and the District of Columbia.

David Beier, J.D.

Mr. Beier has served as a member of our board since December 2017. Mr. Beier brings extensive experience in the biopharmaceutical industry, particularly in areas such as healthcare policy, government affairs, regulatory affairs, pricing, healthcare economics and product commercialization. He is currently a Managing Director at Bay City Capital, where he has been since 2013. He also serves as an appointee of Governor Brown on the California State Government Organization and the Economy Commission. In addition, Mr. Beier is an advisor to the Parker Institute for Cancer Immunotherapy. Previously, Mr. Beier served in the White House as Chief Domestic Policy Advisor to Vice President Gore during the Clinton Administration. He served as an appointee of President Clinton on his Advisory Committee for Trade Policy and Negotiations, on the Institute of Medicine panel on the Future of Health and Human Services, and as an advisor to the President’s Council of Advisors on Science and Technology. Mr. Beier was formerly a partner at Hogan and Hartson and Counsel to the U.S. House of Representatives Committee on the Judiciary. Mr. Beier’s industry experience includes 9 years at Genentech as Vice President, Government Affairs and Policy as well as over 10 years at Amgen as Senior Vice President, Global Government Affairs and Corporate Affairs, where he had responsibility for public policy, coverage and reimbursement, payor planning, healthcare economics, communications and philanthropy. He received his J.D. from Albany Law School at Union University and his undergraduate degree and Colgate University. He is admitted to practice law in New York and the District of Columbia.

Kathryn Falberg

Ms. Falberg has served as a member of the board since September 2017. Previously, she served as Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals plc, a multinational specialty biopharmaceutical company, from March 2012 to March 2014 after serving as Senior Vice President and Chief Financial Officer since December 2009. Her responsibilities at Jazz Pharmaceuticals included strategy, corporate development, corporate communications, and information technology. From 1995 to 2001, Ms. Falberg was with Amgen Inc., a biotechnology company, where she served as Senior Vice President, Finance and Strategy, and Chief Financial Officer; and prior to that she was Vice President, Chief Accounting Officer, and Vice President, Treasurer. Ms. Falberg currently serves as a member of the Board of Directors for the public biopharmaceutical companies Aimmune Therapeutics, Inc., aTyr Pharma, Inc., Axovant Sciences and The Trade Desk, Inc., and recently served on the Board of Directors of Medivation until its acquisition by Pfizer.  Ms. Falberg received an M.B.A. in finance and a B.A. in economics from the University of California, Los Angeles. She is a certified public accountant (inactive).

Kathryn Falberg

Ms. Falberg has served as a member of the board since September 2017. Previously, she served as Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals plc, a multinational specialty biopharmaceutical company, from March 2012 to March 2014 after serving as Senior Vice President and Chief Financial Officer since December 2009. Her responsibilities at Jazz Pharmaceuticals included strategy, corporate development, corporate communications, and information technology. From 1995 to 2001, Ms. Falberg was with Amgen Inc., a biotechnology company, where she served as Senior Vice President, Finance and Strategy, and Chief Financial Officer; and prior to that she was Vice President, Chief Accounting Officer, and Vice President, Treasurer. Ms. Falberg currently serves as a member of the Board of Directors for the public biopharmaceutical companies Aimmune Therapeutics, Inc., aTyr Pharma, Inc., Axovant Sciences and The Trade Desk, Inc., and recently served on the Board of Directors of Medivation until its acquisition by Pfizer.  Ms. Falberg received an M.B.A. in finance and a B.A. in economics from the University of California, Los Angeles. She is a certified public accountant (inactive).

Juan Jaen, Ph.D. (President)

Dr. Jaen has been engaged in all aspects of drug discovery and development for more than 30 years. In 2015, he co-founded Arcus Biosciences together with Terry Rosen. Prior to that, he was co-founder and President/Head of R&D at Flexus Biosciences, until its acquisition by Bristol-Myers Squibb for $1.25 billion. Previously, he was Chief Scientific Officer and Senior Vice President of Drug Discovery at ChemoCentryx. During his tenure there of just under 7 years, Juan led the discovery and progression into the clinic of 8 novel drug candidates in the immunology space. At ChemoCentryx, Juan led the discovery efforts for the multi-year collaboration with GSK, which generated over $100M in non-dilutive milestones and fees. From 1996 to 2006, Juan held various scientific management positions at Tularik (responsible for about 100 scientists in Medicinal and Computational Chemistry, as well as Structural Biology) and then Amgen Inc. (after its acquisition of Tularik in 2004), most recently as Vice President of Chemistry.

From 1983 to 1996, Dr. Jaen held various scientific leadership positions at Parke-Davis/Warner-Lambert. Dr. Jaen holds a Visiting Scholar appointment (ChEM-H) at Stanford University and is a member of the Scientific Advisory Board at Cleave Biosciences. Juan obtained a B.S. degree in Chemistry from Universidad Complutense in Madrid (Spain) and a Ph.D. degree in Organic Chemistry from the University of Michigan. He has co-authored over 100 scientific papers and is an inventor on 50 issued U.S. patents. Dr. Jaen has been responsible for the advancement of over 20 novel molecules into clinical development for diseases including cancer, Alzheimer’s, Crohn’s, RA, diabetes and diabetic nephropathy, psoriasis, asthma, and vasculitis, among others.

Juan Jaen, Ph.D. (President)

Dr. Jaen has been engaged in all aspects of drug discovery and development for more than 30 years. In 2015, he co-founded Arcus Biosciences together with Terry Rosen. Prior to that, he was co-founder and President/Head of R&D at Flexus Biosciences, until its acquisition by Bristol-Myers Squibb for $1.25 billion. Previously, he was Chief Scientific Officer and Senior Vice President of Drug Discovery at ChemoCentryx. During his tenure there of just under 7 years, Juan led the discovery and progression into the clinic of 8 novel drug candidates in the immunology space. At ChemoCentryx, Juan led the discovery efforts for the multi-year collaboration with GSK, which generated over $100M in non-dilutive milestones and fees. From 1996 to 2006, Juan held various scientific management positions at Tularik (responsible for about 100 scientists in Medicinal and Computational Chemistry, as well as Structural Biology) and then Amgen Inc. (after its acquisition of Tularik in 2004), most recently as Vice President of Chemistry.

From 1983 to 1996, Dr. Jaen held various scientific leadership positions at Parke-Davis/Warner-Lambert. Dr. Jaen holds a Visiting Scholar appointment (ChEM-H) at Stanford University and is a member of the Scientific Advisory Board at Cleave Biosciences. Juan obtained a B.S. degree in Chemistry from Universidad Complutense in Madrid (Spain) and a Ph.D. degree in Organic Chemistry from the University of Michigan. He has co-authored over 100 scientific papers and is an inventor on 50 issued U.S. patents. Dr. Jaen has been responsible for the advancement of over 20 novel molecules into clinical development for diseases including cancer, Alzheimer’s, Crohn’s, RA, diabetes and diabetic nephropathy, psoriasis, asthma, and vasculitis, among others.

Yasunori Kaneko, M.D.

Yasunori Kaneko, M.D. has served as a member of our board of directors since May 2015. Dr. Kaneko has been a managing director at Skyline Venture Partners, L.P., a venture capital firm, since 1999. Previously, Dr. Kaneko served on the board of LeukoSite Inc., a biopharmaceutical company, until its merger with Millennium Pharmaceuticals, Inc. in 1999. Dr. Kaneko also served as Chief Financial Officer and Vice President, Business Development at Tularik, Inc., a biopharmaceutical company, from 1992 until 1998. Dr. Kaneko served as a Senior Vice President and Chief Financial Officer of Ionis Pharmaceuticals, Inc., a biopharmaceutical company, which went public in May 1991 during his tenure. Dr. Kaneko began his career at Genentech, where he served in a business development role, a biotechnology company, and as head of corporate finance in the investment banking division of Paribas Capital Markets LTD in Tokyo. Dr. Kaneko received an undergraduate degree and a M.D. degree from Keio University in Tokyo, and an M.B.A. from Stanford Business School. He currently serves as a member of the Dean of Research Advisory Council at Stanford University.

Yasunori Kaneko, MD

Yasunori has served as a member of the board since May 2015. He has been involved in managing and financing life sciences companies since 1981, most recently as a partner at Skyline Ventures which he joined in 1999.  He began his career at Genentech where he led its business development activities for several years.  He was then Project Manager for the launch of Protopin®, the first product marketed by Genentech. In 1987, he became Head of Corporate Finance in the investment banking division of Paribas Capital Markets LTD in Tokyo. He then became Senior Vice President and CFO of Isis Pharmaceuticals (now Ionis Pharmaceuticals) which went public during his tenure there. In 1992, he joined Tularik (acquired by Amgen in 2004) where he served as CFO and VP of Business Development and in other business roles until its public offering in 1999. He served on the board of LeukoSite until its merger with Millennium Pharmaceuticals in 1999. He received an undergraduate degree and medical degree from Keio University in Tokyo and an M.B.A. from Stanford Business School.

Terry Rosen, Ph.D. (CEO)

Dr. Rosen has been leading successful drug discovery and development organizations in the biotechnology and pharmaceutical industries for over 30 years. In 2015, he co-founded Arcus Biosciences, a drug discovery company focused on the treatment of cancer by blocking tumor-induced immunosuppression. Previously, he was co-founder and CEO of Flexus Biosciences, a company created to develop small-molecule drugs to reverse tumor immunosuppression, which was acquired by Bristol-Myers Squibb early in 2015 for $1.25 billion. Prior to Flexus, Terry served as Vice President, Therapeutic Discovery (TD) at Amgen and as the site head for Amgen South San Francisco, having joined Amgen with the acquisition of Tularik in 2004. He was named Amgen Washington site head in 2006, transitioned to a leadership role heading Chemistry Research and Discovery in 2007 and became the head of Protein Sciences in 2011. He and his leadership team were responsible for the creation of the TD organization, a group of 550+ staff responsible for all of Amgen’s large and small molecule drug discovery efforts.

Prior to joining Amgen, Terry held several executive positions at Tularik, including Executive Vice President, Operations, Vice President, Research Operations, and Vice President, Medicinal Chemistry. He has also held scientific and management positions at Pfizer and Abbott Laboratories. Terry serves on the Salk Institute Board of Trustees, the leadership committees of the University of Michigan Undergraduate Research Opportunity Program and Life Sciences Institute, the Berkeley Chemistry Advisory Board, the Caltech Biology & Bioengineering Chair’s Council and the Board of the California Life Sciences Association.

Terry Rosen, Ph.D. (CEO)

Dr. Rosen has been leading successful drug discovery and development organizations in the biotechnology and pharmaceutical industries for over 30 years. In 2015, he co-founded Arcus Biosciences, a drug discovery company focused on the treatment of cancer by blocking tumor-induced immunosuppression. Previously, he was co-founder and CEO of Flexus Biosciences, a company created to develop small-molecule drugs to reverse tumor immunosuppression, which was acquired by Bristol-Myers Squibb early in 2015 for $1.25 billion. Prior to Flexus, Terry served as Vice President, Therapeutic Discovery (TD) at Amgen and as the site head for Amgen South San Francisco, having joined Amgen with the acquisition of Tularik in 2004. He was named Amgen Washington site head in 2006, transitioned to a leadership role heading Chemistry Research and Discovery in 2007 and became the head of Protein Sciences in 2011. He and his leadership team were responsible for the creation of the TD organization, a group of 550+ staff responsible for all of Amgen’s large and small molecule drug discovery efforts.

Prior to joining Amgen, Terry held several executive positions at Tularik, including Executive Vice President, Operations, Vice President, Research Operations, and Vice President, Medicinal Chemistry. He has also held scientific and management positions at Pfizer and Abbott Laboratories. Terry serves on the Salk Institute Board of Trustees, the leadership committees of the University of Michigan Undergraduate Research Opportunity Program and Life Sciences Institute, the Berkeley Chemistry Advisory Board, the Caltech Biology & Bioengineering Chair’s Council and the Board of the California Life Sciences Association.​